Royalty Report: Drugs, Pharmaceuticals, Medical – Collection: 3376

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Pharmaceuticals
  • Medical
  • Supplements
  • Nutrition

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 3376

License Grant
In connection with closing of the Purchase, the Seller assigned all of its rights, assets, know-how and intellectual property rights in connection with program PR1101 and those granted under a Joint Research and Development Agreement, to the Buyer.
License Property
PR1101 is a new therapeutic protein, to be associated with antibiotics.
Field of Use
The Buyer is a Pharma company that is developing therapies for digestive disorders.

IPSCIO Record ID: 6918

License Grant
Seller shall sell, transfer, assign and deliver and cause to be sold, transferred, assigned and delivered to Buyer, and Buyer shall purchase and accept from Seller, all right, title, and interest of the Seller Entities in the following assets, properties and rights (collectively, the Purchased Assets).

The Seller will retain and license to Buyer certain patent and other intellectual property rights relating to the Products pursuant to the License Agreement (as defined below), with the exception of the Altoprev and Fortamet trademarks which will be sold to Buyer.

The Seller will retain all rights and assets relating to the manufacture of the Products, and Buyer will engage Seller to manufacture the Products for Buyer pursuant to the Supply Agreement.

License Property
The Seller Entities own assets used in the business relating to the following product lines (as more fully described herein, collectively, the “Seller Product Lines” or “Products”)
(a) the Altoprev brand products; and
(b) the Fortamet brand products.
Field of Use
Alzheimer’s Field of Use means the administration of lovastatin sodium for the treatment or prevention of Alzheimer’s disease or related APP processing disorders.

IPSCIO Record ID: 281604

License Grant
Buyer shall purchase from the Seller, and the Seller shall sell, assign, transfer, convey, and deliver to Buyer, all of each Seller’s right, title and interest in and to all of the following assets, properties, and rights (the Acquired Assets).
License Property
Business means the business of conducting research and development as well as manufacturing and marketing nutritional supplements, as conducted by the Seller on the Closing Date.

The Acquired Assets include but not limited to Intellectual Property, Inventory, Books and records.

All Intellectual Property, associated goodwill, related licenses and sublicenses (in each case, whether granted or obtained) and other rights, remedies against infringements of, and rights to protect interests in Intellectual Property, which includes all of each Seller’s rights in its trade names, registered and unregistered trademarks, service marks, domain names, and patents.

Field of Use
This agreement pertains to the medical industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.